MYDA Advisors’s Arcutis Biotherapeutics ARQT Stock Holding History

MYDA Advisors’s Portfolio ARQT Stock Details ARQT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.29M	Hold	240,000	–	–	0.94%	23
2026 Q1	$5.65M	Sell	240,000 -25,000	-9%	-$638K	0.93%	31
2025 Q4	$7.7M	Sell	265,000 -205,000	-44%	-$5.25M	1.47%	15
2025 Q3	$8.86M	Buy	470,000 +100,000	+27%	+$1.58M	1.91%	9
2025 Q2	$5.19M	Buy	370,000 +80,000	+28%	+$1.12M	0.91%	33
2025 Q1	$4.54M	Buy	290,000 +90,000	+45%	+$1.27M	0.79%	36
2024 Q4	$2.79M	Buy	200,000 +80,000	+67%	+$877K	0.7%	42
2024 Q3	$1.12M	Buy	120,000 +45,000	+60%	+$444K	0.24%	76
2024 Q2	$698K	Hold	75,000	–	–	0.15%	82
2024 Q1	$743K	Sell	75,000 -145,000	-66%	-$1.08M	0.21%	77
2023 Q4	$711K	Buy	+220,000	New	+$598K	0.24%	59

Other funds holding ARQT

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

MYDA Advisors's ARQT Position: Q2 2026 in Review

MYDA Advisors held its Arcutis Biotherapeutics (ARQT) position steady in Q2 2026 at 240,000 shares worth $6.29M. The position accounts for 0.94% of the portfolio, ranked #23.

MYDA Advisors first reported a position in ARQT in Q4 2023 and has held it in 11 quarters since. The position peaked at $8.86M in Q3 2025. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

MYDA Advisors held 240,000 shares of Arcutis Biotherapeutics worth $6.29M as of Q2 2026.
MYDA Advisors left its Arcutis Biotherapeutics share count unchanged in Q2 2026.
Arcutis Biotherapeutics made up 0.94% of MYDA Advisors's portfolio in Q2 2026, its #23 holding.
MYDA Advisors first reported a position in Arcutis Biotherapeutics in Q4 2023 and has held it in 11 quarters since.
MYDA Advisors's Arcutis Biotherapeutics position peaked at $8.86M in Q3 2025.
272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on MYDA Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.